Encore Presentations
Tuesday, November 14, 2023
08:30 AM–10:00 AM
Abstract
Background: Clostridioides difficile infection (CDI) is a common nosocomial infection that is a globally recognized cause of morbidity and mortality and has a negative impact on health-related quality of life (HRQoL). Patients with recurrent CDI (rCDI) are at a greater risk for clinical sequelae and poor prognosis. Although more information about the management of CDI is now available, there is still a lack of patient experience data in CDI. Thus, we conducted the first systematic literature review (SLR) evaluating the humanistic burden of CDI and the impact of rCDI on patients and their HRQoL.
Methodology: An SLR was conducted to identify peer-reviewed publications assessing rCDI or CDI broadly and HRQoL and attributes of patient-reported outcomes (PROs). The Cochrane Collaboration, Embase, and PubMed databases were utilized for literature searches from 2010 to 2021 in the English language. Empirical studies assessing the impact of CDI on HRQoL or general PROs were included in this SLR.
Results: Of 511 initially identified articles, 21 met study inclusion criteria. Both generic and condition-specific HRQoL measures were used to assess the burden of CDI.
CDI had a negative impact on overall HRQoL, physical, social, emotional, and role (work or professional activities) functioning. CDI had a greater negative impact on the HRQoL of patients with rCDI compared with those with primary CDI. Patients with CDI experienced symptoms that affected their day-to-day activities and reported feeling isolated, depressed, and lonely. Patients were concerned for future recurrences and felt that they would never be free of CDI. Upon successful treatment, significant improvements were observed in physical, social, mental, and overall HRQoL of patients with rCDI.
Conclusion: Patient experience data showed CDI and rCDI are conditions that continue to affect patient functioning despite successful treatment. Patients with CDI need better prevention strategies, psychological support, and treatments that address microbiome disturbance to overcome the burden of this disease.
Funding/Acknowledgement Statement
This study was sponsored by Seres Therapeutics. Writing and editorial assistance was provided by Stevin Joseph, PharmD, and Cheryl Casterline, MA (Peloton Advantage, LLC, an OPEN Health Company, Parsippany, NJ, USA), and funded by Aimmune Therapeutics, a Nestlé Health Science company.
Presenting Author
Sissi V. Pham PharmDAESARA, Inc
Authors
Alpesh Amin MD, MBA, MACP, MHM, FACC, FRCP
AESARA
Edward P. Armstrong PharmD
Strategic Therapeutics; University of Arizona College of Pharmacy
Daniel C. Malone PhD
Strategic Therapeutics; University of Utah College of Pharmacy
DuÅka M. Franić PharmD, MS, PhD
AESARA